The Nomos Corporation is a supplier of planning and delivery technology for IMRT. This precise new treatment approach, which Nomos introduced to the medical community, has been described as the most significant breakthrough in cancer therapy in the past 30 years. IMRT allows an escalated radiation dose to be delivered to the tumour while limiting exposure and damage to nearby healthy tissue. In effect, it is a non-invasive scalpel, cutting out the bad and leaving the good.
More than 10.000 patients have safely received IMRT treatments at the nearly 100 hospitals equipped with Nomos' clinically proven Peacock, Corvus and MIMiC systems in the United States and abroad. This represents over 90 percent of all commercially treated IMRT patients worldwide. In addition to IMRT, Nomos offers BAT, a unique ultrasound-based organ locator used in prostate and other soft tissue cancer treatments. Nomos is also the exclusive licensee for Peregrine, a Monte Carlo-based advanced dose calculation system developed by Lawrence Livermore National Laboratory.
"Nomos Corporation is committed to improving quality of life and the chance for disease-free survival for cancer patients", stated William W. Wells, the Vice President of Sales and Marketing for Nomos Corporation. "Our partnership with Lynmed will allow us to offer state-of-the-art radiation therapy solutions and equipment to medical facilities and clinics throughout China, enabling this county to provide improved patient care for individuals everywhere."
Lynmed Systems, combining the resources of its partners in the USA and China, provides on-line telemedicine and medical data communications services for hospitals in China. "Our state-of-the-art communication infrastructure and strong technical support ability help Lynmed Systems play a leading role in servicing China's major 500 hospitals", stated Harrison Liang, Director of Marketing for Lynmed Systems Inc.